Kurata Izumi, Tsuboi Hiroto, Takahashi Hidenori, Abe Saori, Ebe Hiroshi, Hagiwara Shinya, Umeda Naoto, Kondo Yuya, Ogishima Hiroshi, Suzuki Takeshi, Matsumoto Isao, Hoshi Sujin, Oshika Tetsuro, Sumida Takayuki
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan.
Intern Med. 2015;54(12):1553-7. doi: 10.2169/internalmedicine.54.4274. Epub 2015 Jun 15.
A 36-year-old man with a 16-year history of refractory Behçet's disease (BD)-associated uveitis and chronic renal failure requiring hemodialysis suffered from frequent ocular attacks despite treatment with systemic corticosteroids and cyclosporine A. Following infliximab administration, the patient's BD ocular attack score 24 and visual acuity improved. Although he developed mild acute gastroenteritis, he did not experience any other adverse events. In our review of the literature, we identified seven patients on hemodialysis with inflammatory disease successfully treated with infliximab. Infliximab may be effective and safe in cases of BD and other diseases, including in patients under hemodialysis.
一名36岁男性，有16年难治性白塞病（BD）相关葡萄膜炎病史及慢性肾衰竭需要血液透析，尽管接受了全身性皮质类固醇和环孢素A治疗，仍频繁发生眼部发作。给予英夫利昔单抗治疗后，患者的BD眼部发作评分降低，视力改善。虽然他出现了轻度急性肠胃炎，但未发生任何其他不良事件。在我们的文献回顾中，我们确定了7例接受血液透析的炎症性疾病患者经英夫利昔单抗成功治疗。英夫利昔单抗在BD及其他疾病的病例中可能有效且安全，包括接受血液透析的患者。
